The global CAR-T Cell Therapy Market is experiencing consistent growth, supported by increasing demand, evolving industry requirements, and continuous innovation across the value chain. According to Roots Analysis, the market is projected to expand from The global CAR-T cell therapy market, valued at USD 6.1 billion in 2025, is projected to reach USD 7.7 billion in 2026 and USD 15.6 billion by 2035, with a CAGR of 8.1% during the forecast period 2026 to 2035.

This article provides a concise overview of the market’s current position, major growth trends, key segments, and leading companies. Market Snapshot:

For a quick view of the market’s overall structure, the following snapshot summarizes its major performance indicators. The data below is based on the market assessment presented by Roots Analysis.

Market Size and Trends: Beyond overall market value, several trends are expected to influence demand and adoption during the forecast period. Roots Analysis highlights the following trends as important factors shaping the future of the CAR-T Cell Therapy Market.

▪ Based on product, Carvykti accounts for the largest share of the CAR-T cell therapy market, owing to its strong clinical efficacy and growing adoption in the treatment of multiple myeloma. ▪ Based on the type of therapy, autologous CAR-T cell therapies capture the majority share of the market due to their proven clinical success, established regulatory approvals, and widespread commercial availability. ▪ Amongst different target antigens, CAR-T therapies targeting CD19 account for over 60% of the overall market share owing to their extensive use across multiple B-cell malignancies and strong clinical outcomes. ▪ With respect to target indication, multiple myeloma contributes over 30% of the CAR-T cell therapy market due to the increasing adoption of BCMA-targeted therapies and rising treatment demand among relapsed / refractory patients. ▪ Across geographical regions, North America captures the largest share of the CAR-T cell therapy market owing to the presence of leading therapy developers, favorable reimbursement frameworks, advanced healthcare infrastructure, and high adoption of innovative cell therapies.

Key Market Segments: To identify where growth is concentrated, the market can be evaluated across multiple segments. Roots Analysis segments the CAR-T Cell Therapy Market based on the following segments:

• Historical Trend: Since 2018
• Forecast Period: Till 2035
• Market Size 2026: USD 7.7 billion
• Market Size 2035: USD 15.6 billion
• CAGR (Till 2035): 8.1%
• Key Players Profiled • Autolus • Bristol Myers Squibb • CARsgen Therapeutics • Cellectis • Gilead Sciences • Innovative Cellular Therapeutics • Noile-Immune Biotech • Novartis • Shanghai GeneChem • Sinobioway Cell Therapy • Takara Bio • Wellington Zhaotai Therapies
• Segments Covered • Product • Type of Therapy • Target Antigen • Target Indication • Geographical Regions

Competitive Landscape: The competitive landscape includes established companies, emerging players, and organizations investing in product development, partnerships, and geographic expansion. Roots Analysis profiles the following key players in its CAR-T Cell Therapy Market report. Autolus, Bristol Myers Squibb, CARsgen Therapeutics, Cellectis, Gilead Sciences, Innovative Cellular Therapeutics, Noile-Immune Biotech, Novartis, Shanghai GeneChem, Sinobioway Cell Therapy, Takara Bio, Wellington Zhaotai Therapies

Conclusion The CAR-T Cell Therapy Market is expected to witness steady growth throughout the forecast year, supported by rising demand, evolving industry needs, and ongoing innovation. For a detailed view of market size, segmentation, trends, and key companies, the Roots Analysis report offers a structured and comprehensive assessment of the market opportunity.